Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MACROGENICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- V6KCS3B53JN8
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Glanders is a severe disease that has already been used as a bioweapon. It is naturally an equine disease but can be administered by aerosol for efficient human infection. Even if quickly diagnosed as Burkholderia mallei and treated, antibiotics do not control infections well. No vaccine has been developed, yet is a rational component of any plan for defense. It is increasingly clear that both safe and efficacious vaccines of the future should be based on subunit designs. Therefore, we propose to identify new, subunit vaccine candidates against glanders. We have engaged in a genomic-scale search of all B. mallei coding sequences for protective antigens. Using an aerosol challenge with virulent pathogen, we have sifted 200,000 genomic fragments to a number of lower complexity pools that protect hamsters and mice against lethal disease. This was accomplished by expression library immunization. Our specific approach to developing one or more subunit vaccines will be to 1) reduce the expression library to its individual protective components, 2) to characterize the immune responses correlated with protection and 3) prepare these new B. mallei antigens, and their homologs from the very closely related B. pseudomalllei, in three vaccine delivery modes. These compositions will be intended for testing in the relevant horse and monkey hosts in phase II of this proposal. At the conclusion of this phase I project we will have generated protective subunits and formulated them into three modalities for B. mallei, and perhaps B. pseudomallei, vaccines. The immune responses correlated with protection will be defined, which should facilitate optimal development of this vaccine and those for related pathogens, such as some Brucella and Pseudomonas species.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
11 SBIR/STTR records share this UEI (2002–2004). Reported award amounts total $2,573,564. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards